International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“Negative thyroid transcription factor-1 (TTF-1-Neg) expression in lung adenocarcinomas is associated with worse outcomes when compared to TTF-1-Pos. Despite this, a comprehensive characterization of TTF-1-Neg is lacking in diagnostic evaluation. Di Federico et al dove in to try to change that.”
Title: TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors
Authors: Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti, Subba Digumarthy, Joao V. Alessi, Pooja Gogia, Grace M. Hambelton, Federica Pecci, Maisam Makarem, Malini M. Gandhi, Edoardo Garbo, Andrea De Giglio, Ambrogio Gagliano, Francesca Sperandi, Francesco Gelsomino, Stefano Scalera, Laura Cipriani, Daniele Marinelli, Giuseppe Lamberti, Narek Shaverdian, Jessica Haradon, Tom Nguyen, Emma Voligny, Marc Ladanyi, Jianjun Zhang, Don L. Gibbons, John V. Heymach, Mizuki Nishino, Scott J. Rodig, Kathleen Pfaff, Xinan Wang, Natasha Rekhtman, Lynette M. Sholl, Jia Luo, Bruce E. Johnson, Pasi A. Jänne, Ravi Arvind, Justin F. Gainor, Marcello Maugeri-Saccà, Andrea Ardizzoni, Rebecca S. Heist, Kathryn C. Arbour, Adam J. Schoenfeld, Natalie I. Vokes, Mark M. Awad
Phase 2 Study Evaluates BIO 300 With SBRT in Early-Stage NSCLC and ILD
